GleamWall
中文EN

VALN Valneva SE IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1836564 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.0%
TTM net income YoY-840.6%
TTM EPS YoY-750.0%
Revenue 3-yr CAGR-21.5%
Net income 3-yr CAGR—

Margins

Gross margin38.7%
Operating margin-47.0%
Net margin-66.0%
FCF margin-32.8%
EBITDA margin—

Returns

ROE-80.2%
ROA-25.6%
ROIC (approx.)-34.5%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets73.4%
Debt / equity1.69x
Current ratio2.38x
Interest coverage-1.96x

Cash quality & payout

Operating cash flow / net income0.46x
Accruals ratio-13.9%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-312024Q3*2024-09-302024Q2*2024-06-302024Q1*2024-03-31
Income statement
Revenue47.69M29.41M48.33M49.23M52.94M45.82M38.06M32.75M
Cost of revenue36.07M23.91M24.12M23.04M27.23M25.68M23.47M22.16M
Gross profit11.62M5.50M24.21M26.19M25.71M20.15M14.59M10.59M
R&D expense25.57M27.29M17.49M14.95M25.58M18.88M16.55M13.13M
SG&A expense7.80M10.49M10.07M8.96M10.20M9.71M11.18M11.67M
Operating income-28.11M-37.12M-10.87M-5.96M-20.88M-12.45M-21.55M68.21M
Interest expense24.64M5.67M5.61M5.98M6.27M5.73M4.94M7.04M
Pretax income-51.08M-43.47M-11.81M-7.76M-32.35M-12.96M-25.10M58.92M
Income tax-1.06M882,000-223,0001.47M4.64M-3.72M-166,0008,000
Net income-50.02M-44.35M-11.59M-9.23M-36.99M-9.24M-24.93M58.91M
EPS (basic)———-0.06———0.42
EPS (diluted)———-0.06———0.41
Balance sheet
Cash & equivalents109.65M143.46M161.31M152.99M168.27M156.34M131.41M176.64M
Receivables27.81M20.08M24.12M33.52M35.20M30.36M30.52M27.29M
Inventory50.23M64.29M61.73M61.68M53.66M57.83M48.87M48.59M
Current assets222.54M268.33M284.72M287.05M299.01M303.61M269.15M306.24M
PP&E, netmay include right-of-use assets (IFRS)119.47M123.40M128.47M134.38M138.88M141.65M137.45M136.70M
Intangibles22.35M23.07M23.82M24.60M25.26M33.48M24.19M24.85M
Total assets398.84M448.23M472.62M482.24M500.03M516.61M466.57M502.83M
Current liabilities93.33M150.48M125.66M106.20M114.58M109.16M102.49M116.08M
Short-term debt17.91M58.83M46.02M19.70M20.85M19.45M19.87M22.41M
Long-term debt161.26M108.89M122.36M161.48M166.52M153.13M160.55M159.03M
Total debt179.17M167.72M168.38M181.18M187.37M172.58M180.42M181.45M
Total liabilities292.67M297.75M286.19M306.99M318.78M299.14M300.29M313.60M
Shareholders' equity106.17M150.48M186.43M175.25M181.25M217.47M166.28M189.23M
Net debt69.52M24.26M7.08M28.19M19.10M16.24M49.00M4.81M
Shares outstanding173.42M———162.40M———
Cash flow statement
Operating cash flow-24.51M-17.44M-2.79M-8.15M9.53M-10.48M-37.83M-28.43M
Capital expenditure1.08M668,0001.26M1.40M3.86M5.90M-394,0004.50M
Free cash flow-25.59M-18.11M-4.06M-9.55M5.67M-16.39M-37.44M-32.93M
Investing cash flow-264,000197,000-681,000-961,0004.69M-15.38M895,00086.71M
Financing cash flow-9.36M-556,00014.88M-5.58M-4.59M51.86M-9.13M-7.46M

Free plan shows the latest 8 periods; Pro shows all 20 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.